Composition of Matter Patents: Legal Strategy for Chemical and Life Sciences IP Protection

Under 35 U.S.C. § 101, a composition of matter patent covers any novel combination of chemical elements or compounds with a definite structural identity, and the composition must be non-naturally occurring or modified to confer markedly different characteristics from its natural form. Diamond v. Chakrabarty, 447 U.S. 303 (1980), established that anything under the sun made by man may qualify as patent-eligible, but Mayo v. Prometheus, 566 U.S. 66 (2012), held that natural laws are ineligible regardless of the effort required to apply them. Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576 (2013), further ruled that naturally occurring DNA sequences are products of nature ineligible under § 101, while preserving eligibility for complementary DNA (cDNA) because it is a laboratory-created molecule lacking the non-coding intron sequences of genomic DNA.

The Myriad Genetics case legal impact on Life Sciences patent prosecution has been foundational: the cDNA distinction it established remains the central dividing line between patentable and unpatentable biological compositions today, and companies developing gene therapies or nucleic acid therapeutics must structure composition claims to capture engineered molecules rather than naturally occurring sequences. Biotech patent counsel experienced in § 101 analysis can evaluate whether a proposed biological composition achieves the structural distinctiveness required to survive both USPTO examination and post-grant validity challenges.

The Written Description requirement under 35 U.S.C. § 112(a) demands that the specification demonstrate the inventor possessed the full scope of the claimed invention at filing, and Ariad Pharmaceuticals v. Eli Lilly, 598 F.3d 1336 (Fed. Cir. 2010), established that disclosure of representative species and structural features common to the genus is required as an independent obligation from Enablement. Amgen Inc. .. Sanofi, 598 U.S. 594 (2023), then invalidated antibody claims covering a functional genus of PCSK9 inhibitors because the specification did not enable the full scope without substantial additional experimentation, and applicants should work with patent counseling and prosecution specialists to ensure claim breadth matches the specification's representative examples from the outset.

A Markush Group defines a class of chemical substituents as a closed list using the phrase selected from the group consisting of, allowing a single claim to cover multiple structural variants of a Chemical Compound, and to satisfy § 112, members must share a single structural feature essential to the activity of all compounds in the group. Practitioners must balance the breadth of the defined group against supporting examples, because a Markush Group extending to variants not exemplified in the specification may face Written Description challenges, and the Doctrine of Equivalents interacts with Markush boundaries because prosecution history estoppel may bar equivalents for variants deliberately excluded from the closed list during examination.

A generic manufacturer challenging a pharmaceutical composition patent in Hatch-Waxman ANDA litigation will assert invalidity under §§ 101, 102, 103, and 112 simultaneously while contesting claim scope through Markman claim construction proceedings, and Bio-equivalence data from FDA approval proceedings can be used to argue that the generic product falls within the literal scope of the branded composition claim or that the claim is anticipated by undisclosed prior art. Patent holders in ANDA proceedings should retain patent infringement litigation counsel fluent in both the underlying chemistry and the procedural mechanics of pharmaceutical patent litigation.

A robust composition of matter prosecution strategy begins with a prior art search mapping the relevant chemical space to determine the minimum structural differentiation required for novelty and non-obviousness, and independent claims should be drafted at the broadest structurally supportable scope using Markush Group formats while dependent claims anchor preferred embodiments with the strongest experimental support. A disciplined patent prosecution and portfolio management strategy uses continuation applications to build a layered claim portfolio as clinical data develops, and patent term extension under 35 U.S.C. § 156 can compensate for FDA review delays to extend the effective exclusivity period of a pharmaceutical composition patent.

When a composition of matter patent is challenged through inter partes review (IPR) before the Patent Trial and Appeal Board (PTAB), effective defense strategies include filing a preliminary response challenging the petitioner's claim construction before institution and submitting expert declarations contextualizing the composition's structural novelty within the relevant scientific field. Claim amendments under 37 C.F.R. § 42.121 can add structural limitations distinguishing the composition from asserted prior art, and bio-intellectual property and life sciences licensing counsel can assess whether licensing or settlement structures preserve commercial exclusivity when individual claims are narrowed during PTAB proceedings.